Healthcare Industry News: Simcere Pharmaceutical Group
News Release - February 11, 2011
Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and MarketingNANJING, China, Feb. 11, 2011 (Healthcare Sales & Marketing Network) -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE:SCR ), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the appointment of Mr. Hong Zhao, a highly regarded executive in the Chinese pharmaceutical industry, as its executive vice president of sales and marketing, effective February 12, 2011.
"Mr. Zhao is highly respected in the Chinese pharmaceutical industry," said Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere. "Mr. Zhao has nearly 20 years' experience in the pharmaceutical industry with a proven track record of leadership and performance. We warmly welcome Mr. Zhao who will help strengthen our leadership team and better position our business for sustainable growth."
Mr. Zhao commented, "I am delighted to be joining Simcere, an energetic and promising company that I have long admired for its value and vision. I am looking forward to working with such an innovative team to enhance the competitiveness of Simcere and help make a difference to the healthcare industry in China."
Mr. Hong Zhao joined the industry in 1992. He started as a pharmaceutical sales representative and took on positions of increasing responsibilities in sales & marketing with Xian Janssen and Novartis China. He most recently held the position of Senior Vice President of Novartis Greater China and General Manager of Novartis Shanghai. Mr. Zhao received an EMBA degree from China Europe International Business School (CEIBS), and a bachelor's degree in Medicine from Nanjing Medical University.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR ) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics. The Company has introduced an innovative anti-cancer medication Endu, first-to-market generics such as Bicun and Anxin, and a first-to-market medication Sinofuan. Simcere manufactures and sells drugs in the oncological, cardiovascular, anti-inflammatory and anti-infection therapeutical areas. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence or mortality rates and for which there is a clear demand for more effective pharmacotherapy including cancer and cardiovascular, cerebrovascular, inflammatory and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Source: Simcere Pharmaceutical Group
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.